Evidence map›Paper›PMID 41494657›Full record

ArticleAmerican journal of physiology. Endocrinology and metabolism2026

Hyaluronan 35 prevents endotoxin-mediated dysregulated skeletal muscle proteostasis during ethanol exposure.

Nicole Welch, Pugazhendhi Kannan, Gangarao Davuluri, Annette Bellar, Amy H Attaway, Saurabh Mishra, Jasmin A Cunningham, Avinash Kumar, Ryan Musich, Elif G Ertugral and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Nicole WelchDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.ORCID 0000-0002-4655-5146
Pugazhendhi KannanDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.
Gangarao DavuluriThe Texas A&M AgriLife Institute for Advancing Health Through Agriculture, Texas A&M University, College Station, Texas, United States.
Annette BellarDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.
Amy H AttawayDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.
Saurabh MishraDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.
Jasmin A CunninghamDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.
Avinash KumarDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.
Ryan MusichDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.
Elif G ErtugralCenter for Innovation in Advanced Functional Materials, Department of Chemical and Biomedical Engineering, Cleveland State University, Cleveland, Ohio, United States.
Vandana AgrawalDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.
Isaac L HsuDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.
Terri J HarfordDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, United States.ORCID 0000-0001-6590-0673
Noah L WeislederDepartment of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, United States.
Vidula T VachharajaniDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.
Chandrasekhar R KothapalliCenter for Innovation in Advanced Functional Materials, Department of Chemical and Biomedical Engineering, Cleveland State University, Cleveland, Ohio, United States.
Carol A de la MotteDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.
Laura E NagyDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.ORCID 0000-0002-0580-2809
Srinivasan DasarathyDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, United States.ORCID 0000-0003-1774-0104

Funding

Project Two - Exercise Training Decreases Alcohol Drinking by an FGF21-Dependent MechanismP50AA024333 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy · 2016 to 2026
$19.6M
The Cleveland Digestive Diseases Research Core Center (DDRCC)P30DK097948 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI Fabio Cominelli · 2015 to 2026
$15.6M
Non Alcoholic Steatohepatitis Clinical Research NetworkU01DK061732 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy · 2002 to 2026
$12.2M
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD)- Cleveland Clinic Clinical CenterU01AA026976 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy, David Streem · 2018 to 2026
$3.2M
Integrated therapies for alcohol use and ALD (ITAALD) Network – UTSW Clinical CenterU01AA026975 · NIAAA · UT SOUTHWESTERN MEDICAL CENTER · PI E SHERWOOD BROWN, Mack Clarence Mitchell · 2018 to 2026
$3.0M
Novel mechanism based treatment to improve tissue injury in alcoholic hepatitisR01AA028190 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN, NAGY, LAURA E. · 2020 to 2024
$2.8M
Sarcopenia in cirrhosis is mediated by a hyperammonemic stress responseR01DK113196 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN, HATZOGLOU, MARIA · 2018 to 2021
$2.3M
Specific-sized hyaluronan: a dual targeted therapy for ALDR01AA026764 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI NAGY, LAURA E. · 2018 to 2022
$2.1M
Immuno-metabolic dysfunction in alcohol with sepsisR01AA028763 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI VACHHARAJANI, VIDULA · 2021 to 2025
$2.0M
Mechanisms of Malnutrition in Cirrhosis with Portosystemic ShuntingR01DK083414 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN · 2011 to 2015
$1.8M
Novel therapeutics for alcoholic hepatitis - Cleveland Translational ComponentU01AA021890 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI NAGY, LAURA E. · 2012 to 2017
$1.6M
Mechanisms of Malnutrition in Cirrhosis with Portosystemic ShuntingR01GM119174 · NIGMS · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN · 2017 to 2020
$1.2M
HHS | National Institutes of Health (NIH) AA028190HHS | National Institutes of Health (NIH) R21 AA022742; R01 DK 113196; R01 GM119174; P50 AA024333; U01 AA021890National Science Foundation (NSF) 1337859NHLBI NIH HHS K08 HL168348NIAAA NIH HHS K08 AA028794NIAAA NIH HHS P50 AA024333NIAAA NIH HHS R01 AA026764NIAAA NIH HHS R01 AA028190NIAAA NIH HHS R01 AA028763NIAAA NIH HHS R03 AA032324NIAAA NIH HHS R21 AA022742NIAAA NIH HHS U01 AA021890NIAAA NIH HHS U01 AA026975NIAAA NIH HHS U01 AA026976NIDDK NIH HHS P30 DK097948NIDDK NIH HHS R01 DK083414NIDDK NIH HHS R01 DK113196NIDDK NIH HHS R01 DK133905NIDDK NIH HHS U01 DK061732NIGMS NIH HHS R01 GM119174NIH HHS S10 OD023436NIH HHS S10 OD030398
6 · The paper itself

Abstract

Sarcopenia in alcohol-related liver disease (ALD) is of high clinical significance, but there are no effective treatments. Hyaluronan 35 kDa (HA35), a glycosaminoglycan polymer, modulates responses to Toll-like receptor 4 (TLR4), a lipopolysaccharide receptor, to improve hepatic and macrophage function in ALD. We evaluated skeletal muscle responses to HA35 in preclinical models of ALD. Responses to ethanol, lipopolysaccharide (LPS), and HA35 were studied in differentiated murine C2C12/human-induced pluripotent stem cell (hiPSC)-derived myotubes, and wild-type/HA receptor CD44 knockout (

Indexed as

EthanolHyaluronic AcidLiver Diseases, AlcoholicMuscle, SkeletalProteostasisSarcopeniaAnimalsEndotoxinsHumansHyaluronan ReceptorsLipopolysaccharidesMaleMiceMice, Inbred C57BLMice, KnockoutMuscle Fibers, SkeletalCd44 protein, mouseEndotoxinsEthanolHyaluronan ReceptorsHyaluronic AcidLipopolysaccharidesToll-Like Receptor 4alcohol-related liver diseasehyaluronansarcopeniasignaling

Identifiers

PMID41494657
PMCPMC12782283

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.